PDS Biotech
A clinical stage immunotherapy company with a growing pipeline of infectious disease vaccines and cancer immunotherapies.
In June 2020, the US company announced a co-development agreement with Farmacore Biotechnology for Versamune-CoV-2FC, a vaccine aimed at preventing COVID-19 infection.
Under the collaboration, PDS Biotech and Farmacore will accelerate development of Versamune-CoV-2FC into Phase I clinical testing in Brazil, with initial financial support provided by the Brazilian Ministry of Science, Technology, Innovation and Communication.
Latest PDS Biotech News & Features
2 May 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze